Alector, Inc.

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

Another day, another Alzheimer’s failure. This time it is the turn of Alector, whose AbbVie-partnered anti-TREM2 antibody, AL002, failed in Phase II, and while this is not quite as big a catastrophe

AbbVie is paying $1.4bn in cash for privately held Aliada Therapeutics and its sole clinical candidate – but if ALIA-1758 proves to be a best-in-class disease-modifying therapy for Alzheimer’s disease

While a handful of new Alzheimer’s drugs have made it to market in recent years, some groups are working on other forms of dementia. One such is Vesper Bio , whose sortilin inhibitor VES001 generated